Table 2 Incidence and multiplicity of colonic neoplasia.
From: Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands
Group no. | Treatment | No. of mice | Incidence (no. of mice with neoplasms) | Multiplicity (no. of tumors/mice, means ± SD) | ||||
|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Total | Adenoma | Adeno-carcinoma | Total | Adenoma | Adeno-carcinoma |
1 | AOM/DSS | 10 | 10/10 (100%) | 10/10 (100%) | 10/10 (100%) | 5.2 ± 3.0 | 2.1 ± 1.8 | 3.0 ± 1.8 |
2 | AOM/DSS/0.04% Nimesulide | 10 | 8/10 (80%) | 6/10 (60%)a | 4/10 (40%)b | 1.8 ± 1.7b | 1.2 ± 1.3 | 0.6 ± 1.0c |
3 | AOM/DSS/0.05% Troglitazone | 10 | 9/10 (90%) | 9/10 (90%) | 4/10 (40%)b | 2.5 ± 1.8a | 1.6 ± 1.1 | 1.2 ± 2.5a |
4 | AOM/DSS/0.05% Bezafibrate | 10 | 8/10 (80%) | 7/10 (70%) | 6/10 (60%)a | 2.6 ± 2.5a | 1.1 ± 1.0a | 1.8 ± 2.6 |
5 | 0.04% Nimesulide | 5 | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) | 0 | 0 | 0 |
6 | 0.05% Troglitazone | 5 | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) | 0 | 0 | 0 |
7 | 0.05% Bezafibrate | 5 | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) | 0 | 0 | 0 |
8 | AOM | 5 | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) | 0 | 0 | 0 |
9 | DSS | 6 | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) | 0 | 0 | 0 |
10 | None | 5 | 0/5 (0%) | 0/5 (0%) | 0/5 (0%) | 0 | 0 | 0 |